AbCellera Biologics (ABCL) Operating Leases (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Operating Leases came in at $134.3 million in Q1 2026, up 112.48% YoY from $63.2 million in Q1 2025, and down 2.25% on a QoQ basis from $137.4 million in Q4 2025.
AbCellera Biologics (ABCL) Operating Leases (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of Operating Leases data on file, last reported at $134.3 million in Q1 2026.
- Quarterly Operating Leases rose 112.48% year-over-year to $134.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $134.3 million (up 112.48% YoY) and the FY2025 annual result came in at $137.4 million, up 126.2% from the prior year.
- Operating Leases slipped to $134.3 million in Q1 2026, from $137.4 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $137.4 million in Q4 2025 to a low of $32.8 million in Q2 2022.
- A 5-year average of $82.1 million and a median of $75.2 million in 2023 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases jumped 162.58% — and 2024, when it slipped 21.5%.
- Tracing ABCL's Operating Leases over 5 years: stood at $76.7 million in 2022, then gained by 0.92% to $77.4 million in 2023, then fell by 21.5% to $60.7 million in 2024, then jumped by 126.2% to $137.4 million in 2025, then slipped by 2.25% to $134.3 million in 2026.
- The last three Operating Leases figures came in at $134.3 million (Q1 2026), $137.4 million (Q4 2025), and $137.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 129.95 Mn |
| Mar 31, 2026 | 134.31 Mn |
| Dec 31, 2025 | 137.40 Mn |
| Sep 30, 2025 | 137.05 Mn |
| Jun 30, 2025 | 137.18 Mn |
| Mar 31, 2025 | 63.21 Mn |
| Dec 31, 2024 | 60.74 Mn |
| Sep 30, 2024 | 66.27 Mn |
| Jun 30, 2024 | 66.45 Mn |
| Mar 31, 2024 | 68.08 Mn |
| Dec 31, 2023 | 77.38 Mn |
| Sep 30, 2023 | 75.19 Mn |
| Jun 30, 2023 | 78.08 Mn |
| Mar 31, 2023 | 77.27 Mn |
| Dec 31, 2022 | 76.68 Mn |
| Sep 30, 2022 | 71.59 Mn |
| Jun 30, 2022 | 32.76 Mn |
| Mar 31, 2022 | 36.36 Mn |
| Dec 31, 2021 | 36.41 Mn |
| Sep 30, 2021 | 27.26 Mn |